BIOMAT Database Logo BIOMAT Database Logo

Myelodysplastic syndrome. 2005

Shinji Nakao, and H Joachim Deeg, and Takayuki Ishikawa, and Judith Marsh, and Alan List, and Masao Tomonaga
Cellular Transplantation Biology, Division of Cancer Medicine, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa City, Ishikawa 920-8641, Japan. snakao@med3.m.kanazawa-u.ac.jp

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D009190 Myelodysplastic Syndromes Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA. Dysmyelopoietic Syndromes,Hematopoetic Myelodysplasia,Dysmyelopoietic Syndrome,Hematopoetic Myelodysplasias,Myelodysplasia, Hematopoetic,Myelodysplasias, Hematopoetic,Myelodysplastic Syndrome,Syndrome, Dysmyelopoietic,Syndrome, Myelodysplastic,Syndromes, Dysmyelopoietic,Syndromes, Myelodysplastic
D011878 Radiotherapy The use of IONIZING RADIATION to treat malignant NEOPLASMS and some benign conditions. Radiotherapy, Targeted,Targeted Radiotherapy,Radiation Therapy,Radiation Therapy, Targeted,Radiation Treatment,Targeted Radiation Therapy,Radiation Therapies,Radiation Therapies, Targeted,Radiation Treatments,Radiotherapies,Radiotherapies, Targeted,Targeted Radiation Therapies,Targeted Radiotherapies,Therapies, Radiation,Therapies, Targeted Radiation,Therapy, Radiation,Therapy, Targeted Radiation,Treatment, Radiation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000961 Antilymphocyte Serum Serum containing GAMMA-GLOBULINS which are antibodies for lymphocyte ANTIGENS. It is used both as a test for HISTOCOMPATIBILITY and therapeutically in TRANSPLANTATION. ATGAM,Antilymphoblast Globulins,Antilymphocyte Antibodies,Antilymphocyte Globulin,Lymphocytotoxic Antibodies,Anti-Thymocyte Globulin,Antilymphocyte Immunoglobulin,Antithymocyte Globulin,Antithymoglobulin,Lymphocyte Immune Globulin, Anti-Thymocyte Globulin,Lymphocyte Immune Globulin, Anti-Thymocyte Globulin (Equine),Pressimmune,Anti Thymocyte Globulin,Anti-Thymocyte Globulins,Antibodies, Antilymphocyte,Antibodies, Lymphocytotoxic,Antibody, Antilymphocyte,Antibody, Lymphocytotoxic,Antilymphoblast Globulin,Antilymphocyte Antibody,Antilymphocyte Globulins,Antilymphocyte Immunoglobulins,Antilymphocyte Serums,Antithymocyte Globulins,Antithymoglobulins,Globulin, Anti-Thymocyte,Globulin, Antilymphoblast,Globulin, Antilymphocyte,Globulin, Antithymocyte,Globulins, Anti-Thymocyte,Globulins, Antilymphoblast,Globulins, Antilymphocyte,Globulins, Antithymocyte,Immunoglobulin, Antilymphocyte,Immunoglobulins, Antilymphocyte,Lymphocyte Immune Globulin, Anti Thymocyte Globulin,Lymphocytotoxic Antibody,Serum, Antilymphocyte,Serums, Antilymphocyte
D013234 Stem Cells Relatively undifferentiated cells that retain the ability to divide and proliferate throughout postnatal life to provide progenitor cells that can differentiate into specialized cells. Colony-Forming Units,Mother Cells,Progenitor Cells,Colony-Forming Unit,Cell, Mother,Cell, Progenitor,Cell, Stem,Cells, Mother,Cells, Progenitor,Cells, Stem,Colony Forming Unit,Colony Forming Units,Mother Cell,Progenitor Cell,Stem Cell
D016572 Cyclosporine A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed). Cyclosporin A,Ciclosporin,CsA-Neoral,CyA-NOF,Cyclosporin,Cyclosporine A,Neoral,OL 27-400,Sandimmun,Sandimmun Neoral,Sandimmune,CsA Neoral,CsANeoral,CyA NOF,OL 27 400,OL 27400
D018380 Hematopoietic Stem Cell Transplantation Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms. Stem Cell Transplantation, Hematopoietic,Transplantation, Hematopoietic Stem Cell

Related Publications

Shinji Nakao, and H Joachim Deeg, and Takayuki Ishikawa, and Judith Marsh, and Alan List, and Masao Tomonaga
[Myelodysplastic syndrome].
September 1993, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
Shinji Nakao, and H Joachim Deeg, and Takayuki Ishikawa, and Judith Marsh, and Alan List, and Masao Tomonaga
Myelodysplastic syndrome.
March 1993, Journal of the Indian Medical Association,
Shinji Nakao, and H Joachim Deeg, and Takayuki Ishikawa, and Judith Marsh, and Alan List, and Masao Tomonaga
[Myelodysplastic syndrome].
January 2007, Nihon rinsho. Japanese journal of clinical medicine,
Shinji Nakao, and H Joachim Deeg, and Takayuki Ishikawa, and Judith Marsh, and Alan List, and Masao Tomonaga
[Myelodysplastic syndrome].
May 1989, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
Shinji Nakao, and H Joachim Deeg, and Takayuki Ishikawa, and Judith Marsh, and Alan List, and Masao Tomonaga
[Myelodysplastic syndrome].
March 2008, Nihon rinsho. Japanese journal of clinical medicine,
Shinji Nakao, and H Joachim Deeg, and Takayuki Ishikawa, and Judith Marsh, and Alan List, and Masao Tomonaga
Myelodysplastic syndrome.
July 2008, Indian journal of pediatrics,
Shinji Nakao, and H Joachim Deeg, and Takayuki Ishikawa, and Judith Marsh, and Alan List, and Masao Tomonaga
[Myelodysplastic syndrome].
May 1989, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
Shinji Nakao, and H Joachim Deeg, and Takayuki Ishikawa, and Judith Marsh, and Alan List, and Masao Tomonaga
[myelodysplastic syndrome].
September 1985, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
Shinji Nakao, and H Joachim Deeg, and Takayuki Ishikawa, and Judith Marsh, and Alan List, and Masao Tomonaga
Myelodysplastic syndrome.
January 2005, Annual review of medicine,
Shinji Nakao, and H Joachim Deeg, and Takayuki Ishikawa, and Judith Marsh, and Alan List, and Masao Tomonaga
Myelodysplastic syndrome.
October 1988, Journal of the Indian Medical Association,
Copied contents to your clipboard!